Lexeo Therapeutics, Inc. Investing Cash Flow
Lexeo Therapeutics, Inc. (LXEO) reported Investing Cash Flow of $41.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-12
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $14.26M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $27.46M, a 76.03% increase year-over-year.
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$101.69M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $35.01M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$90.25M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$94.08M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$165.00K.
- Lexeo Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$901.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $41.72M 10-Q · filed 2026-08-12 | -$59.97M derived: sum of 3 quarters · filed 2026-08-12 | -$24.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $27.46M 10-Q · filed 2026-05-11 | -$74.23M derived: sum of 2 quarters · filed 2026-05-11 | -$39.22M derived: sum of 3 quarters · filed 2026-05-11 | -$78.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$101.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$66.68M derived: sum of 2 quarters · filed 2026-03-30 | -$105.85M derived: sum of 3 quarters · filed 2026-08-12 | -$90.25M 10-K · filed 2026-03-30 |
| 2025-09-30 | $35.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.16M derived: sum of 2 quarters · filed 2026-08-12 | $11.44M 10-Q · filed 2025-11-05 | -$82.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$39.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$23.57M 10-Q · filed 2026-08-12 | -$117.16M derived: sum of 3 quarters · filed 2026-08-12 | -$117.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $15.60M 10-Q · filed 2026-05-11 | -$77.98M derived: sum of 2 quarters · filed 2026-05-11 | -$78.07M derived: sum of 3 quarters · filed 2026-05-11 | -$78.28M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$93.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$93.67M derived: sum of 2 quarters · filed 2026-03-30 | -$93.88M derived: sum of 3 quarters · filed 2026-03-30 | -$94.08M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$301.00K derived: sum of 2 quarters · filed 2025-11-05 | -$494.00K 10-Q · filed 2025-11-05 | -$567.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$218.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$411.00K 10-Q · filed 2025-08-14 | -$484.00K derived: sum of 3 quarters · filed 2025-08-14 | -$537.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$193.00K 10-Q · filed 2025-05-12 | -$266.00K derived: sum of 2 quarters · filed 2025-05-12 | -$319.00K derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$126.00K derived: sum of 2 quarters · filed 2025-03-24 | -$165.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$92.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$39.00K 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | -$107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$901.00K 10-K · filed 2024-03-11 | ||
| 2022-09-30 | -$794.00K 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |